Q-omics provides the consensus-scored RPS6P21 profile across patient tissues and cancer cell-line models. RPS6P21 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS6P21 is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, RPS6P21 RNA expression shows 6,586 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, UCEC, and STAD as cancer lineages where RPS6P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6P21 survival associations across molecular data types. RPS6P21 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6P21 RNA expression–survival associations across cancer types. High RPS6P21 expression shows unfavorable associations in KIRC, ACC, LIHC, UVM and CESC, but favorable associations in COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS6P21 RNA expression.
This table summarizes RPS6P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS6P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6P21 shows lower tumor expression in UCEC and THCA and higher tumor expression in PRAD, LIHC and COAD. The UCEC box plot shows higher RPS6P21 RNA expression in normal versus tumor tissue (log2 FC = −0.153, t-test p = .041).
This table shows molecular features associated with RPS6P21 in patient tissues and cancer cell lines. In patient samples, RPS6P21 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
